Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 16/20 | 0.73 |
| ▸ | CSNK2A1 | P68400 | 16/20 | 0.73 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14635589 | 0.88 | CSNK2A2 (0.68) | CSNK2A2CSNK2A1RIPK1 | |
| SCHEMBL14635133 | 0.82 | CSNK2A2 (0.71) | CSNK2A2CSNK2A1RIPK1 | |
| SCHEMBL14634723 | 0.81 | CSNK2A2 (0.73) | CSNK2A2CSNK2A1 | |
| SCHEMBL14634725 | 0.81 | CSNK2A2 (0.73) | CSNK2A2CSNK2A1 | |
| SCHEMBL14635284 | 0.81 | CSNK2A2 (0.80) | CSNK2A2CSNK2A1RIPK1 | |
| SCHEMBL15890949 | 0.81 | CSNK2A2 (0.80) | CSNK2A2CSNK2A1RIPK1 | |
| SCHEMBL14635566 | 0.80 | CSNK2A2 (0.72) | CSNK2A2CSNK2A1PIK3CDRIPK1 | |
| SCHEMBL15890982 | 0.80 | CSNK2A2 (0.72) | CSNK2A2CSNK2A1PIK3CDRIPK1 | |
| SCHEMBL14635237 | 0.79 | CSNK2A2 (0.64) | CSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL12284140 | 0.74 | CSNK2A2 (0.67) | CSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791257-B2 | Substituted pyrrolotriazines as protein kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | STK25, MAP3K15, MAP3K5 | CSNK2A2 123/4885CSNK2A1 84/4885PIK3CD 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.